[go: up one dir, main page]

SMT201400159B - Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina - Google Patents

Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina

Info

Publication number
SMT201400159B
SMT201400159B SM201400159T SM201400159T SMT201400159B SM T201400159 B SMT201400159 B SM T201400159B SM 201400159 T SM201400159 T SM 201400159T SM 201400159 T SM201400159 T SM 201400159T SM T201400159 B SMT201400159 B SM T201400159B
Authority
SM
San Marino
Prior art keywords
dimethylphenylsulfanil
piperazine
phenyl
salts
liquid formulations
Prior art date
Application number
SM201400159T
Other languages
English (en)
Inventor
Diego Heidi De Lopez
Svend Treppendahl
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400159(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SMT201400159B publication Critical patent/SMT201400159B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
SM201400159T 2009-04-24 2014-10-29 Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina SMT201400159B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21454009P 2009-04-24 2009-04-24
DKPA200900531 2009-04-24
PCT/DK2010/050084 WO2010121621A1 (en) 2009-04-24 2010-04-16 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Publications (1)

Publication Number Publication Date
SMT201400159B true SMT201400159B (it) 2015-01-15

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400159T SMT201400159B (it) 2009-04-24 2014-10-29 Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina

Country Status (35)

Country Link
US (4) US8940746B2 (it)
EP (1) EP2421534B1 (it)
JP (1) JP5722879B2 (it)
KR (1) KR101779214B1 (it)
CN (2) CN102405048A (it)
AR (2) AR076400A1 (it)
AU (1) AU2010238946B2 (it)
BR (1) BRPI1015338C1 (it)
CA (1) CA2759456C (it)
CL (1) CL2011002631A1 (it)
CO (1) CO6450649A2 (it)
CR (1) CR20110554A (it)
DK (1) DK2421534T3 (it)
DO (2) DOP2011000319A (it)
EA (1) EA021122B1 (it)
ES (1) ES2512719T3 (it)
GE (1) GEP20135938B (it)
HK (1) HK1206732A1 (it)
HR (1) HRP20140880T1 (it)
IL (1) IL215362A0 (it)
MA (1) MA33298B1 (it)
MX (1) MX2011011119A (it)
MY (1) MY155288A (it)
NZ (1) NZ596431A (it)
PL (1) PL2421534T3 (it)
PT (1) PT2421534E (it)
RS (1) RS53539B1 (it)
SG (1) SG175124A1 (it)
SI (1) SI2421534T1 (it)
SM (1) SMT201400159B (it)
TN (1) TN2011000504A1 (it)
TW (1) TWI461224B (it)
UA (1) UA106985C2 (it)
WO (1) WO2010121621A1 (it)
ZA (1) ZA201107731B (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2421534T3 (da) 2009-04-24 2014-10-13 Lundbeck & Co As H Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin
BR112015006075B1 (pt) * 2012-09-19 2022-10-04 Sandoz Ag Composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina
EP3016937B1 (en) 2013-07-01 2017-08-30 LEK Pharmaceuticals d.d. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
GB201419261D0 (en) 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
ES2819831T3 (es) 2016-02-08 2021-04-19 H Lundbeck As Síntesis de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]piperazina
US9820984B1 (en) 2016-07-01 2017-11-21 H. Lundbeck A/S Dosing regimens for fast onset of antidepressant effect
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
HRP20080478T3 (hr) 2003-04-04 2009-02-28 H. Lundbeck A/S Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
AU2007260356B2 (en) * 2006-06-16 2013-01-24 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US8722684B2 (en) * 2006-06-16 2014-05-13 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
DK2421534T3 (da) 2009-04-24 2014-10-13 Lundbeck & Co As H Flydende formuleringer af salte af 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin

Also Published As

Publication number Publication date
TN2011000504A1 (en) 2013-05-24
HK1206732A1 (en) 2016-01-15
HRP20140880T1 (hr) 2014-11-07
TWI461224B (zh) 2014-11-21
MX2011011119A (es) 2011-11-04
US20190167667A1 (en) 2019-06-06
AR076400A1 (es) 2011-06-08
BRPI1015338C1 (pt) 2021-08-10
AU2010238946A1 (en) 2011-12-08
BRPI1015338A2 (pt) 2016-05-31
CL2011002631A1 (es) 2012-04-09
UA106985C2 (uk) 2014-11-10
EA021122B1 (ru) 2015-04-30
AR122051A2 (es) 2022-08-10
TW201041604A (en) 2010-12-01
IL215362A0 (en) 2011-12-29
CN102405048A (zh) 2012-04-04
JP2012524735A (ja) 2012-10-18
ZA201107731B (en) 2013-02-27
KR101779214B1 (ko) 2017-09-18
SG175124A1 (en) 2011-12-29
JP5722879B2 (ja) 2015-05-27
PL2421534T3 (pl) 2014-12-31
EA201171287A1 (ru) 2012-04-30
WO2010121621A1 (en) 2010-10-28
NZ596431A (en) 2012-12-21
PT2421534E (pt) 2014-10-29
US8940746B2 (en) 2015-01-27
EP2421534A1 (en) 2012-02-29
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
US9475748B2 (en) 2016-10-25
MA33298B1 (fr) 2012-05-02
US10034876B2 (en) 2018-07-31
RS53539B1 (sr) 2015-02-27
CN104693145A (zh) 2015-06-10
CA2759456C (en) 2017-10-31
CA2759456A1 (en) 2010-10-28
BRPI1015338B1 (pt) 2021-01-05
DOP2011000319A (es) 2012-02-29
BRPI1015338B8 (pt) 2021-05-25
KR20120022809A (ko) 2012-03-12
US20120035188A1 (en) 2012-02-09
MY155288A (en) 2015-09-30
GEP20135938B (en) 2013-10-10
DK2421534T3 (da) 2014-10-13
AU2010238946B2 (en) 2013-03-28
DOP2012000211A (es) 2013-03-31
SI2421534T1 (sl) 2014-11-28
ES2512719T3 (es) 2014-10-24
CO6450649A2 (es) 2012-05-31
US20150094316A1 (en) 2015-04-02
US20170224677A1 (en) 2017-08-10
US10857149B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
SMT201400159B (it) Formulazioni liquide si sali di 1-[2-(2,4-dimetilfenilsolfanil)fenil] piperazina
IL214178A0 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine
LT3034497T (lt) 3,5-diamino-6-chlor-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamidas
EP2577970A4 (en) SCRIPT-BASED ACCESS TO HIDDEN MULTIMEDIA PLANTS
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
SMT201300063B (it) Procedimento per preparazione di composti piperazinici e loro sali idrocloruri
EP2421513A4 (en) NEW INDOMETHACINFORMULATION
IL217914A0 (en) New compositions of 1-[2-(2'4-dimethyl-phenylsulfanyl)-phenyl]piperazine
EP2656872A4 (en) ELECTRODE PAD FOR IONTOPHORESIS
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
ITMI20110647A1 (it) Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
IT1397895B1 (it) Procedimento per la compensazione di quadratura
CY1115793T1 (el) Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης
ITBG20070014U1 (it) Dispositivo di taglio fissa - erogatore per bottiglie di superalcolici
IT1395936B1 (it) Sali di febuxostat
FR2926459B1 (fr) Perfectionnement pour fauteuil roulant